ACADIA Pharmaceuticals, Inc. To Announce Fourth Quarter And Full Year 2005 Results On March 1, 2006

SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. , a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended December 31, 2005 on Wednesday, March 1, 2006, after the U.S. financial markets close.

Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, Vice President and Chief Financial Officer, will host a conference call and webcast on Wednesday, March 1, 2006 at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and provide an update on the company's development programs.

The conference call may be accessed by dialing 866-713-8562 for participants in the U.S. or Canada and 617-597-5310 for international callers (reference passcode 17247135). A telephone replay of the conference call may be accessed through March 15, 2006 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 28684341). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until March 15, 2006.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

Contacts: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations Thomas H. Aasen, Vice President and Chief Financial Officer (858) 558-2871

CONTACT: Lisa Barthelemy, Director, Investor Relations, or Thomas H.Aasen, Vice President and Chief Financial Officer, both of ACADIAPharmaceuticals Inc., +1-858-558-2871